Review on production of 89Zr in a medical cyclotron for PET radiopharmaceuticals

Journal of Nuclear Medicine Technology

Volumn 41, Issue 1, 2013, Pages 35-41

  Kasbollah, Azahari ^a,b   Eu, Peter ^c   Cowell, Simon ^a   Deb, Pradip ^a  

^a RMIT UNIVERSITY   (Australia)

^b MALAYSIAN NUCLEAR AGENCY   (Malaysia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

89Zr radionuclide; Monoclonal antibodies; Positron emission tomography (PET); Radiolabeling; Yttrium solid target

Indexed keywords

FLUORODEOXYGLUCOSE F 18; UNCLASSIFIED DRUG; ZIRCONIUM; ZIRCONIUM 89; DIAGNOSTIC AGENT; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYCLOTRON; DRUG HALF LIFE; HUMAN; NUCLEAR MEDICINE TECHNICIAN; POSITRON EMISSION TOMOGRAPHY; PROFESSIONAL DEVELOPMENT; ANIMAL; CHEMISTRY; EQUIPMENT; METHODOLOGY; RADIOCHEMISTRY; REVIEW;

ANIMALS; CYCLOTRONS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RADIOISOTOPES; RADIOPHARMACEUTICALS; ZIRCONIUM;

EID: 84874984571     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnmt.112.111377     Document Type: Article

References (41)

1. Hans Lundqvist ML, Tolmachev V. Positron emission tomography. Eur J Nucl Med. 1998;19:537-552.
2. Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schreyögg J. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. J Nucl Med Tech. 2010;38:6-17.
3. Eckelman WC. The status of radiopharmaceutical research. Int J Rad Appl Instrum B. 1991;18:iii-vi.
4. Ruth TJ. The production of radionuclides for radiotracers in nuclear medicine. Reviews of Accelerator Science and Technology. 2009;02:17-33.
5. Wrenn FR. GML, Handler P The use of positron-emitting radioisotopes for the localization of brain tumors. Science. 1951;113:525-527.
6. Anger HO. Radioisotope camera instrumentation in nuclear medicine. In: Hine, G J ed. Instrumentation in Nuclear Medicine. New York, NY: Academic; 1967: 485-552.
7. Aronow S. Positron scanning instrumentation in nuclear medicine. In: Hine, G J ed. Instrumentation in Nuclear Medicine. New York, NY: Academic; 1967:461-483.
8. Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med. 1975;16:210-224.
9. Lawrentschuk N, Davis ID, Bolton DM, Scott AM. Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship. BJU Int. 2006;97:916-922.
10. Boswell CA, Brechbiel MW. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol. 2007;34:757-778.
11. 89Zr for the labelling of antibodies with a positron emitter. Appl Radiat Isot. 1994;45:1143-1147.
12. 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271-1281.
13. Phelps ME. Molecular imaging and its biological applications. Eur J Nucl Med Mol Imaging. 2004;31:1544.
14. 89Zr, a potential PET antibody label. Int J Rad Appl Instrum [A]. 1990;41:789-790.
15. Verel I, Visser GW, Boerman OC, et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm. 2003;18:655-661.
16. Nayak TK, Brechbiel MW. Radioimmunoimaging with longer-lived positronemitting radionuclides: potentials and challenges. Bioconjugate Chemistry. 2009;20:825-841.
17. Lewis Jason S, Singh Rajendra K. Welch Michael J. Long lived and unconventional PET radionuclides. Molecular Imaging in Oncology; 2008:283-292.
18. Hohn A, Zimmermann K, Schaub E, Hirzel W, Schubiger PA, Schibli R. Production and separation of "non-standard" PET nuclides at a large cyclotron facility: the experiences at the Paul Scherrer Institute in Switzerland. Q J Nucl Med Mol Imaging. 2008;52:145-150.
19. Van Dongen GA, Visser GW, Lub-de Hooge MN, De Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist. 2007;12:1379-1389.
20. Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009;36:729-739.
21. Bowen H. The biogeochemistry of the elements. In: Trace Elements in Biochemistry. London, U.K.: Academic Press. 1966:173-239.
22. 89Zr for antibody labelling and positron tomography. J Labelled Comp Radiopharm. 1986;23:1296-1297.
23. Zweit J, Downey S, Sharma HL. Production of no-carrier-added zirconium-89 for positron emission tomography. Int J Rad Appl Instrum [A]. 1991;42:199-201.
24. Kumbhar PP, Lokhande CD. Electrodeposition of yttrium from a nonaqueous bath. Met Finish. 1995;93:28, 30-31.
25. 89Zr reaction. Kerntechnik. 2010;75:298-302.
26. Saha GB, Porile NT, Yaffe L. (p, xn) and (p, pxn) Reactions of Yttrium-89 with 5-85-MeV Protons. Phys Rev. 1966;144:962.
27. Liu S. Bifunctional coupling agents for radiolabeling of biomolecules and targetspecific delivery of metallic radionuclides. Adv Drug Deliv Rev. 2008;60:1347-1370.
28. Greenwood NN, Earnshaw A. Chemistry of the Elements. Oxford, UK: Pergamon Press; 1984.
29. Meijs WE, Herscheid JDM, Haisma HJ, Pinedo HM. Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. Int J Rad Appl Instrum [A]. 1992;43:1443-1447.
30. 89Zr-porphyrin for positron label of monoclonal antibodies. J Labelled Comp Radiopharm. 1991;30:326.
31. Meijs WE, Haisma HJ, Klok RP, et al. Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. J Nucl Med. 1997;38: 112-118.
32. Meijs WE, Haisma HJ, Van Der Schors R, et al. A facile method for the labeling of proteins with zirconium isotopes. Nucl Med Biol. 1996;23:439-448.
33. Perk L, Vosjan M, Visser G, et al. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging. 2010;37: 250-259.
34. Vosjan MJWD, Perk LR, Visser GWM, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5:739-743.
35. 89Zr-Labeled Trastuzumab, A Humanized Monoclonal Antibody Against Epidermal Growth Factor Receptor 2. Molecular Imaging and Contrast Agent Database (MICAD) [database online]. Bethesda, MD: National Library of Medicine, NCBI; 2004-2009; 2010. Available from: http://micad.nih.gov.
36. 89Zr-trastuzumab for HER2/neu ImmunoPET imaging. J Nucl Med. 2009;50:974-981.
37. 89Zrtrastuzumab for clinical HER2 immunoPET imaging. J Clin Oncol. 2007;25 (18S):3508.
38. 89Zrtrastuzumab and PET Imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.
39. Sampath L, Kwon S, Ke S, et al. Dual-Labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med. 2007;48:1501-1510.
40. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276-2282.
41. Liu Y, Welch MJ. Nanoparticles labeled with positron emitting nuclides: advantages, methods, and applications. Bioconjug Chem. 2012;23:671-682.